FDA Authorizes Kernel x Cybin Ketamine Study

This week we received FDA authorization to measure ketamine’s psychedelic effect on the brain using Kernel Flow with our partner Cybin.

It is exciting to explore the possibilities of psychedelic therapeutics by enabling longitudinal brain activity measurement before, during and after a psychedelic experience, leading to quantifying what has been subjective patient reporting.

61856ce7f69d07807d2e5eb8 Cybin Kernel

Explore Experiences Near You

Visit our state of the art locations and be on the frontier of neuroscience.

Get the Kernel App

Point your camera at the QR code to download Kernel.

Sign up and manage studies, view reports, and connect your wearables.

Download the app today!

QR code to app store